Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study

BACKGROUND: Abiraterone acetate plus prednisone with androgen deprivation therapy is a standard treatment option for patients with high-risk metastatic castration-sensitive prostate cancer (mCSPC). However, no data are available on the optimal subsequent treatment option in patients treated with abi...

Descripción completa

Detalles Bibliográficos
Autores principales: Koroki, Yosuke, Taguri, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928798/
https://www.ncbi.nlm.nih.gov/pubmed/36443540
http://dx.doi.org/10.1007/s11523-022-00929-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928798/
https://www.ncbi.nlm.nih.gov/pubmed/36443540
http://dx.doi.org/10.1007/s11523-022-00929-3

Ejemplares similares